Premium
Evaluation of a new Recombinant BCG which Contains Mycobacterial Antigen ag85B–mpt64 190–198 –mtb8.4 in C57/BL6 Mice
Author(s) -
Qie Y. Q.,
Wang J. L.,
Zhu B. D.,
Xu Y.,
Wang Q. Z.,
Chen J. Z.,
Wang H. H.
Publication year - 2008
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2007.02048.x
Subject(s) - immunogenicity , antigen , esat 6 , mycobacterium tuberculosis , immune system , immunology , tuberculosis , virology , biology , recombinant dna , adjuvant , antibody , mycobacterium bovis , bcg vaccine , vaccination , gene , medicine , genetics , pathology
Tuberculosis (TB) caused by Mycobacterium tuberculosis continues to be one of the major public health problems in the world. The eventual control of this disease will require the development of a safe and effective vaccine. Bacille Calmette‐Guerin (BCG), the only vaccine against TB, is not perfect for its limited ability to protect against the adult form of TB. Some improvements of TB vaccines relied to strengthening the immunogenicity and/or persistence of genetically modified recombinant BCG (rBCG) strain. Antigen 85B (Ag85B) and Mtb8.4 are importantly immunodominant antigens of M. tuberculosis , and both are very promising vaccine candidate molecules. MPT64 190–198 , is presented to CD8 + T cells during mycobacterial infections. In this study, we combined these above genes into one recombinant gene of ag85B–mpt64 190–198 –mtb8.4 . Then we constructed the new rBCG containing this united gene. This rBCG can induce an increased Th1‐type immune response in mice, characterized by an elevated level of interferon‐γ in antigen‐stimulated splenocyte culture and a strong IgG2a antibody response. Also, it can elicit longer immune responses than BCG. The results show that this rBCG is a promising candidate for further study.